IMRICOR MEDICAL SYSTEMS INC (IMR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IMR - IMRICOR MEDICAL SYSTEMS INC

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.65
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.94

20 Nov
2024

0.055

OPEN

$0.89

6.21%

HIGH

$0.94

175,069

LOW

$0.87

TARGET
$1.08 14.9% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
IMR: 1
Title FY24
Forecast		 FY25
Forecast
EPS (cps) - 8.6 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-21.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.9 M
Book Value Per Share xxxxxxxxxxxxxxx-7.6
Net Operating Cash Flow xxxxxxxxxxxxxxx-19.6 M
Net Profit Margin xxxxxxxxxxxxxxx-3,675.61 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-
Return on Invested Capital xxxxxxxxxxxxxxx-386.76 %
Return on Assets xxxxxxxxxxxxxxx-210.55 %
Return on Equity xxxxxxxxxxxxxxx-
Return on Total Capital xxxxxxxxxxxxxxx-247.69 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-19.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx14 M
Total Debt xxxxxxxxxxxxxxx16 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx1 M
Price To Book Value xxxxxxxxxxxxxxx-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx13.45 %
Cost of Goods Sold xxxxxxxxxxxxxxx3 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx24 M
Research & Development xxxxxxxxxxxxxxx12 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

13/11/2024

1

Speculative Buy

$1.08

14.89%

Morgans increases its target for Imricor Medical Systems to $1.08 from 94c to reflect rising confidence in growth for the overall cardiac ablation segment and the positioning of the company's technology. The Speculative Buy rating is retained.

A number of major Medtech companies are increasing their investment in this segment, highlight the analysts.

The broker reminds investors Imricor is the only company capable of conducting cardiac ablations in an MRI, whereas current procedures are conducted using x-ray fluoroscopy.

FORECAST
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -8.59 cents.
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -6.03 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

IMR STOCK CHART

FNArena News on IMR

1
FNArena Corporate Results Monitor – 29-08-2024

Aug 29 2024 - Australia
2
Next Week At A Glance – 22-26 July 2024

Jul 19 2024 - Weekly Reports
3
Australian Broker Call *Extra* Edition – Aug 16, 2023

Aug 16 2023 - Daily Market Reports
4
Dr Boreham’s Crucible: Imricor Medical Systems

Oct 17 2022 - Small Caps
5
Australian Broker Call *Extra* Edition – Sep 14, 2022

Sep 14 2022 - Daily Market Reports

Latest Medical Equipment & Devices News

1
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
2
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
3
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
4
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
5
ResMed Silences The Doubters

Apr 29 2024 - Australia
6
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
7
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
8
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
9
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
10
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps